 Regeneron Pharmaceuticals Inc NASDAQ: REGN will acquire Checkmate Pharmaceuticals Inc NASDAQ: CMPI for 10.50 per share, equivalent to a total equity value of approximately 250 million. Checkmate is a clinical-stage biopharmaceutical company focused on proprietary. 